The Eyes Have It: Optimizing the Treatment of AMD and DME (Enduring)


The Eyes Have It: Optimizing the Treatment of AMD and DME (Enduring)

Topic: Ophthalmology
Relevant Terms: Diabetic Macular Edema, Age-Related Macular Degeneration
Primary Audience: Ophthalmologists, Retinal Specialists
Launch Date: 03-Jan-14
Credits: 1.5 AMA PRA Category 1 Credits
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Summarize existing data on the available agents used to treat diabetic macular edema (DME) and age-related macular degeneration (AMD)
  2. Discuss the evidence supporting current guideline recommendations for the diagnosis and treatment of DME and AMD
  3. Describe the mechanisms of action of novel agents used in the treatment of DME and AMD


    David S. Boyer, MD
    Retinal-Vitreous Associates Medical Group
    Los Angeles, CA
    Jeffery S. Heier, MD
    Director, Vitreoretinal Service
    Ophthalmic Consultants of Boston
    Boston, MA
    Michael S. Ip, MD
    Associate Professor
    University of Wisconsin
    Department of Ophthalmology and Visual Sciences
    Madison, WI
    Instructions on How to Receive Credit
    • Participants must review the materials on accreditation information, target audience, learning objectives, and disclosure information.
    • Complete the 3 rounds of questions, post-test, and evaluation.
    • After passing the post-test, print out your electronic CME certificate.
    • In order to successfully complete this activity learners must achieve a minimum of 70% on the post-test.
    Target Audience
    The primary target audience for these activities is comprised of retinal specialists, although the education is appropriate for comprehensive ophthalmologists who manage and treat patients with DME and AMD.
    This activity is supported by an educational grant from Genentech.

    This activity is sponsored by the Institute for Continuing Healthcare Education.
    Accreditation Statement
    The Institute for Continuing Healthcare Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
    The Institute designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)Physicians should only claim credit commensurate with the extent of their participation in the activity.
    It is the policy of the Institute to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All persons in control of content must disclose any significant financial interest or other relationships that may affect the content of this activity.

    Relationships are abbreviated as follows: E, Educational Planning Committee; G, Grant/research support recipient; A, Advisor/review panel member/educational planning committee; C, Consultant/Independent Contractor; SS, Stock shareholder; SB, Speaker bureau; PE, Promotional Event Talks; H, Honoraria; O, Other.
    David S. Boyer, MD, (Chair) has disclosed the following relevant financial relationships that have occurred within the past 12 months: Alcon, Allergan, Genentech, Neurotech/A; Alcon, Aerpio, Allegro, Allergan, Bausch & Lomb, Bayer, Genentech, KalVista, Neurotech, Novartis, Regeneron, Roche, ThromboGenics/C; Allergan, Genentech/SB; and Allegro/S.
    Jeffrey S. Heier, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Acucela, Aerpio, Allergan, Bausch & Lomb, Bayer, Dutch Ophthalmic, Endo Optiks, Forsight, Genzyme. Heidelberg Engineering, Kanghong, Notal Vision, Ohr Pharmaceutical, Ophthotech, QLT, Regeneron, Roche, Sequenom, Thrombogenics, Vertex, Xcovery/C; and Aerpio, Alcon, Alimera, Allergan, Fovea, Genentech, Genzyme, GlaxoSmithKiline, Neovista, Notal Vision, Novartis, Ophthotech, Paloma, Regeneron/G.
    Michael S. Ip, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Eye Technology, Ltd., Genentech, Neuronetics, Valeant/C; and Allergan/G.
    Peer Reviewer
    Christina Ohnsman, MD, has disclosed the following relevant financial relationships that have occured within the past 12 months: Alcon/A,SB.
    Medical Writer
    Tim Donald as disclosed that he has no relevant financial relationships specific to the subject matter of this activity that have occurred within the past 12 months.
    Activity Development & Management Team
    Cathy Pagano, CCMEP; Allison Muller, Pharm.D, D.ABAT;  Scott Kober, MBA, CCMEP; April Reynolds MS, ELS; Sandra Davidson; and Megan Small; are employees of the Institute and are collectively responsible for the planning, development, and management of this CME activity. These individuals have disclosed that they have had no relevant financial relation­ships specific to the subject matter of this activity that have occurred within the past 12 months.
    Product Disclosure
    This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    The educational content of this activity has been peer reviewed and validated to ensure that it is a fair and balanced representation of the topic, based on the best available evidence.Con
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 5.0+ for Mac OSX 10.5 and above

    For video playback, install the latest version of Flash or Quicktime.
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above

    For additional technical support, please send an email to  
    General Disclosure and Copyright Statement
    The opinions expressed in this publication are those of the participating faculty and not those of the Institute for Continuing Healthcare Education (the Institute), Genentech, Inc., or any manufacturers of products mentioned herein.

    This information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a healthcare professional regarding diagnostic and treatment options of a specific patient's medical condition. In no event will the Institute be responsible for any decision made or action taken based upon the information provided in this activity.

    Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosages, and contraindications. This recommendation is particularly important for new or infrequently used products.

    Copyright 2014. Institute for Continuing Healthcare Education (the Institute). All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means electronic or mechanical—without first obtaining written permission from the Institute.
    The Institute reserves the right to cancel or modify the activity content, faculty, and activities if necessary.